田七注射液配合促红素治疗慢性肾衰竭贫血46例

目的:观察田七注射液配合重组人促红素注射液治疗慢性肾衰竭贫血的临床疗效。方法:将90例慢性肾衰竭贫血患者随机分为两组,治疗组46例,对照组44例,两组均采用一般治疗,对照组加用重组人促红素注射液等药物治疗;治疗组在对照组的基础上采用田七注射液治疗,治疗2个疗程后进行疗效比较。结果:治疗组总有效率91.3%,对照组为70.5%,两组比较,差异有非常显著性意义(P<0.05)。治疗组在降低血肌酐、血尿素氮及升高血红蛋白等方面明显优于对照组。结论:田七注射液可以改善肾性贫血,降低血肌酐,减少促红细胞生成素的用量,减少应用EPO引起的血压升高等副作用,延缓CRF恶化,提高患者的生活质量,值得临床推广应用。

Clinical Observation on Tianqi Injection Combined with Recombinant Human Erythropoietin Injection Treating 46 Cases of Chronic Renal Anemia

Objective:To observe the effect of Tianqi injection combined with Recombinant Human Erythropoietin Injection on cure of chronic renal anemia.Methods:90 patients with chronic renal anemia were randomly divided into the treating group(n=46)and the control group(n=44).Base on the routine therapy,Recombinant Human Erythropoietin Injection was used to the control group,Tianqi Injection was used to the treating group on base of the control group,8 weeks constituted two treatment courses.The changes of symptom,physical sign and laboratory examinations were observed before and after treatment.Results:The total effective rate was 91.3% in treating group and 70.5% in control group(P<0.01).The treating group was effectively better than the control group on reducing the levels of Ccr and Bun and rising the HGB and so on.Conclusion:Tianqi Injection could improve chronic renal anemia,reduce the Ccr level,reduce the dosage of Recombinant Human Erythropoietin Injection,reduce the side effect as elevation of blood pressure caused by EPO,delay CRF progression and improve the quality of life of patients.So it was worthy of applying to clinical therapy further.